JP Morgan downgraded Takeda Pharma from Overweight to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/8/2026 | Mkt Perform → Outperform | Bernstein | |
| 1/13/2026 | Overweight | Morgan Stanley | |
| 4/2/2025 | Equal-Weight → Overweight | Morgan Stanley | |
| 3/16/2023 | $20.00 | Neutral → Buy | BofA Securities |
| 7/19/2022 | $21.00 → $24.00 | Market Perform → Outperform | Cowen |
| 10/7/2021 | Overweight → Equal-Weight | Morgan Stanley |
3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches Achieved Latest FY2025 Management Guidance Takeda is Entering a New Era & Transforming for Growth Acceleration Takeda ((4502, NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch
TORONTO, May 5, 2026 /CNW/ - Takeda Canada Inc. ("Takeda") announced that REVESTIVE® (teduglutide for injection) will now be reimbursed by BC PharmaCare for eligible pediatric and adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.1 Coverage is subject to specific criteria.2 For people living with SBS, reimbursed access can help reduce reliance on parenteral support, which includes intravenous administration of nutrition, fluids, and electrolytes."We welcome the Government of B.C.'s decision to reimburse REVESTIVE for people living with Short
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda ((TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrate
Bernstein upgraded Takeda Pharma from Mkt Perform to Outperform
Morgan Stanley resumed coverage of Takeda Pharma with a rating of Overweight
Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight
A proven people‑focused commercial strategist with extensive global experience to lead Takeda Canada's next chapter of growth and impact.TORONTO, March 2, 2026 /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Alan Walshe as General Manager for Canada. Alan brings 17 years of experience with Takeda and its predecessor companies, most recently serving as Global Head of Commercial Strategy for the Plasma‑Derived Therapies Business Unit."Alan's depth of commercial expertise and global perspective, combined with his people‑focused leadership sty
SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br
− Rhonda Pacheco to Succeed Julie Kim, Who Was Appointed to Be Takeda's Next CEO Takeda ((TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, effective September 29, as president of Takeda's U.S. Business Unit and will be a member of the Takeda Executive Team. Pacheco will succeed Julie Kim, who was appointed by the Takeda Board of Directors to succeed Christophe Weber as president and Chief Executive Officer (CEO) of Takeda in June 2026. With Pacheco's appointment, Kim will focus on preparing for the CEO transition, which includes serving as interim head of the Global Portfolio Division. This press r
FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches Achieved Latest FY2025 Management Guidance Takeda is Entering a New Era & Transforming for Growth Acceleration Takeda ((4502, NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda ((TAK) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that conven
Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% at Actual Exchange Rates (AER); Impact of VYVANSE® Generics is Tapering Off Core Operating Profit Declined by 3.4% at both CER and AER Year to Date Reported Operating Profit Increased by 1.2% at AER Year to Date, Lower Restructuring Expenses More Than Offset Impairment Takeda ((4502, NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The comp
SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)
SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)
SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)